HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / HEOR Feature / Invoke a 1980’s Law to Lower Cost of Remdesivir for COVID-19, says 31 State Attorneys General

Invoke a 1980’s Law to Lower Cost of Remdesivir for COVID-19, says 31 State Attorneys General

A coalition of attorneys general (AG) have requested the U.S. Department of Health and Human Services to invoke a federal patent law to lower prices of remdesivir for COVID-19, with the hopes that this will also increase the supply of the drug.  The bipartisan group has addressed the HHS, FDA and NIH and requested these federal agencies to retain patent rights from Gilead Sciences, the developers of remdesivir, to ease potential shortages and lower the drug’s prices.

According to reporting in USA Today, the attorneys general letter stated “The 1980 Bayh-Dole Act allows federal agencies to retain patent rights if a drug company charges too much or fails to reasonably ‘alleviate health or safety needs’ of consumers”. If federal agencies refuse the request, the group wants “march-in” rights to be assigned to states.

AG members of the coalition are publicly stating that they believe Gilead’s pricing is not reasonable, and that drug prices cannot be left to market forces when the research was funded in part by taxpayer dollars.  Other coalition members stated that Gilead has failed to meet public health and safety needs.  The letter is signed by attorneys general of 31 states.

Gilead has responded with a strongly worded statement disputing the AG claim that there won’t be enough remdesivir, since the drug will only be used in the more severe cases. Their statement notes their $1 billion investment to expand manufacturing capacity, including partnering with multiple other manufacturing partners globally.  The company expects to manufacture 2 million courses of therapy, expected to meet or exceed projected patient demand.  Clinical trials on remdesivir have shown that 74% of patients receiving the drug recovered by day 14 of hospitalization compared with 59% of those who did not get the drug, and remdesivir patients had lower mortality rates than those who did not receive the treatment.

Read more here: https://www.usatoday.com/story/news/health/2020/08/04/bipartisan-coalition-attorneys-general-today-asked-u-s-department-health-and-human-services-invoke-f/5580087002/

 

(Source:  Alltucker K, USA Today, August 4, 2020).



You might also be interested in:

  • Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020
  • COVID-19 Vaccine Pricing: Are the Manufacturers Signaling… 08/07/2020
  • Jeff Anderson Joins OPEN Health as European Lead for OPEN VIE… 06/16/2020
  • Scientist.com to Acquire HealthEconomics.Com, the World’s… 12/15/2020
  • Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
  • ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
  • How HEOR Professionals Can Be Force Multipliers in the Fight… 10/06/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute